Ippei Otomaru1, Teruhito Takakuwa1, Yoshimi Miyagi2, Ayano Nishiura1, Akiko Miura1, Taku Araki1, Yotaro Fujitani1, Ryosuke Yamamura1, Hideto Senzaki2, Kensuke Ohta1 (1.Hematology, Osaka Saiseikai Nakatsu Hospital, Japan, 2.Pathology, Osaka Saiseikai Nakatsu Hospital, Japan)
Session information
Poster Session
Sat. Oct, 13
Poster Session 2-25 MM: Others (1)
Sat. Oct 13, 2018 5:10 PM - 5:50 PM Poster2 (Osaka International Convention Center, 5F Main Foyer)
Chair: Takayuki Tamayashi (Department of Hematology, Saitama Medical Center,Saitama Medical University)
Saori Ito, Akinori Oh, Junpei Soeda (Japan Medical Affairs, Takeda Pharmaceuticals Company Limited, Tokyo, Japan)
Ryosuke Fujiwara1,23, Hirokazu Tanaka1,23, Kentaro Serizawa1,23, Hitomi Kaneko2,23, Yuji Shimura3,23, Kensuke Ohta4,23, Shin-Ichi Fuchida5,23, Aya Nakaya6,23, Junya Kanda7,23, Hideo Yagi8,9,23, Katsuya Wada10,23, Satoru Kosugi11,23, Nobuhiko Uoshima12,23, Hirohiko Shibayama13,23, Takae Kohara13,23, Eiji Nakatani14,23, Hitoji Uchiyama15,23, Yoko Adachi16,23, Masato Iida17,23, Tsuneyoshi Hamada18,23, Mitsuhiro Matsuda19,23, Akifumi Takaori-Kondo7,23, Shosaku Nomura20,23, Chihiro Shimazaki5,23, Masayuki Hino21,23, Junya Kuroda4,23, Masafumi Taniwaki22,23, Kazunori Imada2,23, Yuzuru Kanakura13,23, Itaru Matsumura1,23 (1.Hematolog and Rheumatology, Kindai University, Osaka, Japan, 2.Hematology, Osaka Red Cross Hospital, Osaka, Japan, 3.Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 4.Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan, 5.Hematology, JCHO Kyoto Kuramaguchi Medical Center, Kyoto, Japan, 6.Hematology and Oncology, Kansai Medical University Medical Center, Osaka, Japan, 7.Hematology and Oncology, Kyoto University, Kyoto, Japan, 8.Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan, 9.Hematology, Kindai University Nara Hospital, 10.Hematology, Matsushita Memorial Hospital, Osaka, Japan, 11.Internal Medicine (Hematology), Toyonaka Municipal Hospital, Osaka, Japan, 12.Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan, 13.Hematology and Oncology, Osaka University, Osaka, Japan, 14.Biostatistics and Data Science, Osaka University, Osaka, Japan, 15.Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 16.Hematology, Kobe Central Hospital, Hyogo, Japan, 17.Internal Medicine, Kawasaki Hospital, Hyogo, Japan, 18.Hematology, Kyoto-Katsura Hospital, Kyoto, Japan, 19.Hematology, PL General Hospital, Osaka, Japan, 20.First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 21.Hematology, Osaka City University, Osaka, Japan, 22.Molecular Diagnostics Therapeutics, Kyoto Prefectural University of Medicine, Kyoto, Japan, 23.Kansai Myeloma Forum, Osaka, Japan)
Koichiro Minauchi, Naoki Miyashita, Hajime Senjo, Shinpei Harada, Tomohiro Yamakawa, Junko Iwasaki, Shojiro Takahashi, Kohei Okada, Akio Shigematsu, Shuichi Ota, Masahiro Ogasawara, Naoki Kobayashi, Masahiro Imamura (Department of Hematology, Sapporo Hokuyu Hospital, Japan)
Masato Komuro1, Shotaro Hagiwara2, Naoki Kondo1, Tomiteru Togano1, Junji Tanaka2, Hiroyuki Terakado1 (1.National Center for Global Health and Medicine, Tokyo, Japan, 2.Tokyo Women's Medical University, Tokyo Japan)
[PS2-25-6] Predicting treatment response and survival of multiple myeloma with the XBP-1 gene module
Xuzhang Lu1, Xueyi Yu1, Zhuxia Jia1, Wenmin Han1, Jinyuan He1, Rong Xiao1, Xiaohui Cai1, Ayaz Li2, Weiya Wang1, Xiaolong Fan2 (1.The Affiliated Changzhou No.2 People's Hosptial of Nanjin Medical University, Changzhou, People's Republic of China, 2.Beijin Normal University, Beijing, People's Republic of China)
Pavel Kotoucek1, Roumen Bezergianov2, Robert Enright3, Waseem Nagi1, Zuzana Ondrusova4, Alberto Orfao5, Zdenka Stefanikova4, Jan Sedlak6 (1.Mid Essex Hospital Services NHS Trust, Broomfield Hospital, Chelmsford, United Kingdom of Great Britain and Northern Ireland, 2.Counseling Services, Arizona State University, Phoenix, United States of America, 3.Educational Psychology, University of Wisconsin-Madison, Madison, United States of America, 4.Slovak Myeloma Society, Bratislava, Slovak Republic, 5.Salamanca Cancer Centre, Salamanca, Spain, 6.Biomedical Centre, Slovak Academy of Sciences, Bratislava, Slovak Republic)